Regulatory perspectives: one academic viewpoint from the United States.
The development of new drugs to treat vascular dementia and other conditions in which cognitive impairment is due at least in part to vascular pathology will require future interaction among academic, industry, and government regulatory clinicians and scientists. This article offers the author's perspective on the positive involvement of the Food and Drug Administration in development of conceptual frameworks and practical approaches to treatment of conditions characterized by vascular burden of the brain.
Whitehouse
Peter
P
Neurology, Neuroscience and Psychiatry, Case Western Reserve University, Cleveland, Ohio 44106-7125, USA. pjw3@cwru.edu
D000368:Aged; D015140:Dementia, Vascular / Q000188:drug therapy*; D033161:Government Regulation; D006801:Humans; D007391:International Cooperation; D007400:Interprofessional Relations; D014481:United States; D014486:United States Food and Drug Administration